C3i, a Centre of Excellence for Commercialisation and Research, will accelerate access to innovative therapies in immuno-oncology and regenerative medicine for patients. Operating in Montreal, Canada, C3i offers an integrated structure for the development, translation and commercialisation of these ground breaking therapies. Acting as a \one-stop-shop\ solution for the development, translation, and commercialisation of cancer immunotherapy, C3i combines four interacting units: - GMP Manufacturing Unit for Regenerative Medicine and Cancer Immunotherapy - Biomarker-Diagnostic Unit - Clinical Research Unit and a CRO - Innovation and Commercialisation Unit
C3i Address
Hôpital Maisonneuve-Rosemont, Pavillon Rachel Montreal, QC CAN